Asensus Surgical Stock Is Coiling for the Next Move Higher


On May 18, I suggested to Asensus Surgical (NYSEAMERICAN:ASXC) investors that there’s no need to dump your ASXC stock. So far, that optimistic call is working out well.

an image of a microscope
Source: Shutterstock

The share price at that time was $2.01, and it has reached $3.47 since then. That’s a substantial gain in a short period of time, but there could be much more room for upside movement.

Understanding the price action of ASCX stock will be imperative, yet it’s important to get the full picture. This means delving into Asensus Surgical’s potentially transformative digitized surgical technology.

As we’ll see, Asensus’s chief product is gaining traction and, eventually, could become a mainstay in the field of minimally invasive surgical equipment.

ASXC Stock at a Glance

Let’s start by rewinding the clock a bit. On Feb. 23, 2021, TransEnterix announced its intention to change the company’s name to Asensus Surgical.

As a result, TRXC transitioned into ASXC stock.

The share price closed the first trading day of 2021 at around $1.17, but it didn’t stay there for very long. In short order, the buyers asserted themselves and staged a spectacular rally.

Thus, on Feb. 10, the ASXC stock price reached a 52-week high of $6.95. Then came a major retracement, with the shares falling back to $1.52 on April 20.

May was a much better month for the long-side investors, though, and it appears that a turnaround is already in the works.

By June 3, the stock was already approaching the $2.70 level and generally trending upwards. Long-term, it’s entirely possible that the buyers will assert themselves again and revisit the $7 area.

Digitizing the Interface

Asensus is known for having developed innovative surgical technologies such as the SPIDER device and the SurgiBot System.

Today, however, the company’s chief product is the robotic laparoscopic surgical platform known as the Senhance Surgical System.

This is a system that uses augmented intelligence to “provide unmatched performance and patient outcomes through machine learning.”

Asensus’ objective with the Senhance Surgical System is to provide the driving force behind greater control in laparoscopy. With this, there’s the potential to improve patient outcomes and even save lives.

An essential feature of the Senhance Surgical System is haptic feedback. This means that if a pressure threshold is reached, the platform can enhance a surgeon’s sensing of that pressure/tension through alerts.

Also vital is the Senhance Surgical System’s eye-tracking camera control. This feature enables the platform to sense a surgeon’s eye activity, thereby allowing for more precise control over a camera used in the surgical process.

On top of all that, the Senhance Surgical System implements 3D high-definition visualization, which can provide surgeons with additional intelligence regarding the depth and spatial relation of the patient’s organs.

Expanding the Reach

Clearly, there are tremendous benefits to bringing the Senhance Surgical System to the health-care system, not just in the U.S. but globally.

Of course, this is easier said than done. It’s good to know though that Asensus has already signed two new agreements with two hospitals in Europe this year.

Not only that, but reportedly a hospital in Asia “purchased a previously leased Senhance System at the end of the lease term.”

Slowly but surely, Asensus is gaining traction in expanding the presence of its proprietary technology. In fact, the company expects to install 10 to 12 new Senhance Surgical Systems this year.

Moreover, during the first quarter of 2021, more than 500 procedures were performed globally using the Senhance Surgical System. That signifies an increase of 3% compared to the first quarter of 2020.

The Takeaway

Patient investors are witnessing what could be a turning point in the price action of ASXC stock.

This could also be a turning point in digitized surgical technology, as the Senhance Surgical System offers the possibility of better precision for surgeons, and improved outcomes for patients.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. 

Read More: Penny Stocks — How to Profit Without Getting Scammed 

On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.

Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today   

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC